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Abstract
2,4-Dinitrophenol (DNP) is a well-documented mitochondrial uncoupler that was
widely used as a dieting drug in the 1930’s. It was later banned in 1938 due its negative
side effects which included extreme weight loss, the formation of cataracts, skin rashes,
and death. Triclosan (TCS) is a common antimicrobial agent that is a component in
soaps, toothpastes, and other household products. In addition to its antimicrobial role,
TCS has been found to alleviate skin inflammation and dermatitis. However, TCS has
also been linked to several health issues including increased cases of asthma and allergy,
developmental problems, and decreased fertility. Previous studies in the Gosse laboratory
found that TCS inhibits the primary functions of mast cells, key players in the immune
system. More recent studies have found that in addition to increasing oxygen
consumption, TCS significantly inhibits ATP production in rat basophilic leukemia cells,
clone 2H3 (RBL-2H3) at non-cytotoxic doses with an EC50 of 7.5 µM to 9.6 µM. These
results strongly indicate that, like DNP, TCS is a mitochondrial uncoupler.
Since DNP is a known, dangerous mitochondrial uncoupler, it serves as a useful
comparison to assess the potential danger of TCS. In this study, cultured RBL-2H3 cells
were exposed to increasing concentrations of DNP and were assessed for ATP production
and cytotoxicity. DNP was found to significantly inhibit ATP production at non-cytotoxic
doses with an EC50 of 389 µM to 677 µM. These results indicate that TCS is ~60-fold
more potent as a mitochondrial uncoupler in RBL cells than in DNP. More related,
comparative research with DNP is needed to fully explore triclosan’s mitochondrial
toxicity.
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1. Introduction
1.1 2,4-Dinitrophenol
2,4-Dinitrophenol (DNP) is a known mitochondrial uncoupler that was widely
used as a weight loss drug in the 1930’s1. As a dieting drug, it was found to increase the
rate of metabolism in patients by 50% or more1. In the 1930’s, it was discovered that
DNP caused several negative side effects and there were several deaths associated with
its use1. DNP was banned as a dieting drug in the U.S. in 19382. DNP is currently sold
over the internet as a workout powder or tablet, commonly marketed to body builders.
However, there have been many cases of patients dying of hyperthermia in the
emergency room as a result of using those DNP products3-6. In addition to its use as a
weight loss drug, DNP is also used as a component of dyes, wood preservatives,
explosives, herbicides and fungicides1,2,4.
DNP has been found to cause hyperthermia3-6. Also DNP has also been found to
cause a variety of other health problems. Before it was banned, it was discovered that
DNP could cause skin rashes1 and the formation of cataracts7. Increasing concentrations
of DNP were found to cause potassium accumulation in rat kidneys, as well as inorganic
phosphate accumulation throughout their bodies8. In humans, DNP was found to cause
kidney injury10. Prolonged exposure in humans can cause a yellow discoloration of the
skin and urine8. Other reported problems associated with continued use include deafness,
confusion, and coma8. DNP has been found to cause reproductive and development issues
in rats9. It has also been found that exposure to DNP via skin contact and inhalation is
toxic11.
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Recently, there has been a lot of research done investigating possible positive
application of DNP. At controlled doses, DNP was found to prevent obesity in mice12. A
derivative of DNP, designed specifically to function in the liver, was found to reverse
hypertriglyceridemia, fatty liver, and whole-body insulin resistance in rats that were fed a
high fat diet13. DNP has the ability to stimulate signaling responses in the cerebral cortex,
and may have some potential therapeutic applications14. DNP can lower the levels of
reactive oxygen species (ROS) in mitochondria15. This feature of DNP has been found to
help protect cells from buildup of ROS in response to heat stress16, cold stress17, and
exposure to sodium nitroprusside18.
Limited research has been done on the effect of DNP exposure on mast cells, the
cell type primarily studied by the Gosse laboratory. Mast cells are key players in the
immune system that, through the process of degranulation, release pro-inflammatory
mediators in response to antigen or allergen. One study found that DNP exposure
increased the degranulation in mast cells19. Two other studies came to the opposite
finding20,21. Based on the information availaboratoryle, no conclusion can be made as to
how DNP affects mast cells at this time.

1.2 Triclosan
Triclosan (TCS) is a broad spectrum, antibacterial agent22,23 used in a wide variety
of consumer products such as soaps, toothpastes, cleaners, and many other household
products at concentrations of roughly 10mM23,24. The use of TCS in those products is
currently not regulated by the U.S. government. TCS has been found in both land25 and
aquatic26 environments, most notably in wastewater treatment plants25,26. TCS has also
been detected in a variety of aquatic animals 27,28.
2

TCS has also been detected in humans29. In one study the human test subjects
who had ingested roughly 1 tablespoon of TCS-containing mouthwash were later found
to have TCS in their blood streams at an average concentration of 1µM30. Another study
found TCS in the milk of nursing mothers who had used TCS-containing personal care
products31. Based on TCS detection in urine samples, a 2003-2004 study estimated that
75% of the United States population is likely exposed to TCS32. TCS can be absorbed
both orally33,34 and through skin exposure35-37.
As stated earlier, the primary function of TCS is to prevent bacterial growth by
inhibiting the bacterial fatty acid synthesis. During bacterial fatty acid synthesis in E.
coli, TCS binds to both NAD+ and the enol-acyl carrier protein reductase (FabI) at its
substrate site to form a non-covalent bi-substrate38. This prevents the process of fatty acid
synthesis from going forward and thus prevents bacterial colonies from expanding as new
cell membranes cannot be made.
Studies have found that certain bacteria are, or can become, resistant to TCS. One
study found that TCS usage was associated with a high risk of developing resistance in
Staphylococcus aureus and E.coli39. Another study found that a mutation in the fabI gene
of E.coli led to a change in the substrate binding site of the FabI protein, the mutated
gene coding for FabI[G93V] protein38. TCS had a significantly lower affinity for the
mutated binding site on FabI[G93V] reducing its inhibition of fatty acid synthesis38. Yet
another study found that, in vivo, Salmonella typhimurium exposure to TCS could lead to
variants of the bacteria that were both resistant to TCS and other antibiotics40. A review
study went so far as to postulate that risks of TCS resistant bacteria developing from
usage of TCS containing soap outweighed the benefits of TCS’s antimicrobial
3

properties41. Use of TCS soap in an Italian hospital led to an outbreak of Pseudomonas
aeruginosa42, which is intrinsically resistant to TCS43. Pseudomonas aeruginosa is
resistant to TCS due to the presence of a MexAB-OprM efflux system44. Exposure to
TCS can lead to variants that hyper-express that efflux system and thus have higher
resistance to other antibacterial drugs44. A review article focusing on TCS use in regular
consumer products did not find any correlation between TCS presence and antibacterial
resistance, but also stated that more intensive studies were needed45.
TCS is small, hydrophobic, and ionizable, with a pKa around 7.9. In laboratory
experiments it has been found to be stable at up to 200°C46. TCS in its deprotonated form
can be broken down during prolonged exposure to heat and sunlight in the environment47.
In its protonated form, TCS is considered toxic to aquatic animals due to its ability to
cross cellular membranes48. However, more studies need to be done to assess TCS’s role
in mammalian biology and how it affects mammalian health.

1.3 Triclosan Epidemiology
Triclosan (TCS) is used for a wide array of medical applications. TCS, used as a
component of toothpaste, has been found to be effective at preventing gingivitis and
plaque buildup49-51, and has been shown to limit the progress of periodontitis52. In skin
care use, TCS has been shown to prevent skin inflammation caused by sodium lauryl
sulphate53, nickel sulphate54, and histamine55. TCS has been shown to be a safe and
effective option for treating dermatitis57, thought to be due to it preventing
Staphylococcus aureus growth58. In one study, patients who used topical steroids, along
with TCS, to treat dermatitis required less steroid use (P< 0.05) than a control group to
treat their condition56. TCS has also been shown to be very effective at treating both acute
4

eczematous dermatitis59 and acute dermatomycoses60. TCS is also commonly used to
sterilize surgical sites and tools and has been found to be quite effective at preventing
surgical site infections61.
However, TCS exposure has also been linked to a variety of health problems.
TCS has been associated with increased occurrence of allergies and asthma62-64. One
study found that reported atopic asthma increased 34% among individuals exposed to
TCS63. Another study found that there was a statistically significant increase in reported
allergy or hay fever among individuals who had TCS in their urine and were under the
age of eighteen64. TCS was also associated with an increased chance of food allergies in
male test subjects62.
There have been several conflicting studies done on TCS’s role as an endocrine
disruptor and the possible health effects caused by its endocrine disruption. One study
found that among females aged 6-8, there was a slight inverse relationship between TCS
exposure and pubic hair development67. Several studies have found that TCS has negative
effects on human fertility, likely due to it being an endocrine disruptor65. The results of
one study found that among participants in the highest quartile of TCS urine
concentrations (>71.7 ng/ml) there was a decreased rate of fecundity65. A laboratory
study found that preimplantation exposure to TCS could lead to implementation failure in
mice66. Another study found that among individuals in Japan who had suffered a
spontaneous abortion, 28.3% had significantly higher concentrations of TCS in their
urine as compared to normal pregnacies68. This effect of high TCS concentration causing
spontaneous abortion was then replicated in laboratory mice68. However, other studies
have not found any association between TCS exposure through health care products and
5

negative health effects caused by endocrine disruption69-71. One study found that 0.3%
TCS in toothpaste did not cause any notable negative effect on thyroid function70 while
another did not find any short term impact of TCS exposure on hormone function71. It
should, however, be noted that those previous two studies were conducted by a group of
researchers affiliated with the University of Queensland (New Zealand). This school is
closely associated with Colgate Pamolive, and receives both scholarships72,75 and
corporate sponsorship73,74 from the company. Colgate Pamolive manufactures and
markets the toothpaste Colgate Total, which contains TCS.

1.4 Mitochondrial Uncoupling and Oxidative Phosphorylation
Mitochondria are organelles that have important roles in a wide variety of cellular
functions76. One of those functions is the energy producing process of oxidative
phosphorylation. During oxidative phosphorylation, adenosine diphosphate (ADP) is
phosphorylated by the enzyme ATP synthase to adenosine triphosphate (ATP), the
energy currency of the cell. H2O is also produced as a byproduct77. ATP synthase derives
its energy from the proton gradient maintained by the proton pumps of the electron
transport chain, which pump protons from inside the mitochondrial matrix to the
intermembrane space while also shuttling electrons into reaction with O2 to produce H2O.
Proton pumping produces a proton gradient, in which more protons are on the outside of
the inner mitochondrial membrane than on the matrix side. In typical, healthy
mitochondria, the only way a proton can flow back into the matrix is through a pore in
the ATP synthase complex. The flow of a proton through ATP synthase, down its
concentration gradient releases free energy, which ATP synthase uses to catalyze the
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phosphorylation of ADP. This process is the primary way in which human cells produce
energy, with less efficient alternatives including anaerobic lactate formation77.
Mitochondrial uncouplers interfere with oxidative phosphorylation by providing a
way for protons to flow down their concentration gradient, back into the matrix, without
passing through ATP synthase. In an uncharged, protonated state, proton ionophore
mitochondrial uncouplers can pass through the inner mitochondrial membrane. In
general, more potent mitochondrial uncouplers have a pKa above 679. Once inside, the
uncoupler can dissociate a proton, thereby disrupting the proton gradient and decreasing
ATP production78. The dissipation of the proton gradient is detrimental to oxidative
phosphorylation and can be lethal to the cell, as it will have to find other ways to produce
energy. Uncoupling also leads to an increase on O2 consumption as the electron transport
chain tries to re-establish the proton gradient77. Thus the main ways of evaluating
mitochondrial uncoupling are measuring O2 consumption and ATP production80,81.

1.5 Health Effects of Mitochondrial Uncouplers
As stated before, use of DNP as a dieting drug can have severe effects on human
health. When used as a dieting drug, DNP uncouples mitochondria, causing them to
dissipate the potential energy produced by the electron transport chain as heat instead of
using it for ATP production. This causes the human body to quickly burn through its fat
stores as it tries desperately to get mitochondrial proton gradients re-established. In many
cases, this results in death by hyperthermia.
Human cells that are part of adipose brown tissue (brown fat) are actually able to
take advantage of mitochondrial uncoupling to produce heat by using the inner
7

mitochondrial membrane uncoupling protein thermogenin82. In laboratory research, the
process of thermogenesis in brown fat was found to be critical to the energy regulation of
laboratory rats and potentially had a role in the prevention of obesity83.
The mitochondrial uncouplers CCCP and carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP) have been shown to have effects on rat basophilic leukemia
(RBL) mast cells, the main cell type used in this study84-86. One study showed that CCCP
exposure both decreases RBL ATP production and significantly inhibits its primary
function in media that did not contain glucose (the presence of glucose allows cultured
cells to adequately produce energy through glycolysis, it is common to use media not
containing glucose to force cultured cells to rely on oxidative phosphorylation)85.

1.6 Mast Cells
Previous research in the Gosse laboratory has found that TCS both uncouples
mitochondria in mast cells and inhibits their primary function114. Mast cells are key
players in the immune system, with roles in type I hypersensitivity104 and allergic
immune response115. Their primary function is to release pro-inflammatory mediators
from their many intracellular granules. Mast cells are ubiquitous in the body and, in
addition to their role in allergic responses, have roles in immune responses to infectious
disease and carcinogenesis, as well as neurological disorders such as autism and
anxiety84,87,88. According to recent research, mast cells may also play a role in modulating
behavior89. Mast cells are a good model for studying the effects of TCS and DNP because
they are so ubiquitous (located in the mouth, skin, and connective tissue116-118) and thus
would very likely be exposed to TCS, used in epidermal and oral care, and DNP, which is
ingested orally.
8

Human mast cell development starts in the bone marrow from
CD34+/CD117+/CD13+ pluripotent precursor cells90. From the bone marrow, immature
mast cells travel through the blood stream to peripheral connective or mucosal tissue.
This is where they complete their development. Next KIT is activated after stem cell
factor (SCF)-induced KIT dimerization and auto-phosphorylation119. This key step
enables mast cell maturation. SCF plays an important role in the maturation process,
controlling mast cell survival and cell adhesion to either other cells or substrates. SCF
also allows for the proliferation and differentiation of mast cells91.
Being present throughout the body, mast cells are often the first responders to
viruses, bacteria, and parasites104. Mast cells are important to both the innate and adaptive
immune systems. The role of mast cells in the immune system is to release proinflammatory mediators from their internal granules. These mediators include histamine,
tryptase, serotonin, and chymase92. Of those, histamine is the most well-known,
significant effector93 In addition to the release of those mediators, mast cell activation
also stimulates the synthesis of lipid mediators such as leukotrienes and prostaglandins,
cytokines, and chemokines94. As well as initiating the inflammatory response, these
mediators also have roles in angiogenesis, tumorigenesis, and cellular hyperplasia.
Degranulation usually occurs as a result of IgE receptor crosslinking, however, mast cells
can also be activated by a variety of different mechanisms121-124.
Research suggests that the distribution of mediators among granules is
heterogeneous and that the release of specific mediators depends on the tissue
microenvironment in which a mast cell is located95. The particular physiological role of a
mast cell is dependent on the mediators contained in its granules. Mast cells rely on
9

surface receptors to sense their environment. These receptors include Fcε, Fcγ, TLRs,
major histocompatibility complexes (MHC) classes I and II, KIT, and various
interleukins96. In type I allergic responses, mast cells are activated by IgE crosslinking to
the FcεRI surface receptor.

1.6.1 RBL-2H3 Cell Line
Rat basophilic leukemia cells (RBL) cells, clone 2H3 (RBL-2H3) are a commonly
used mast cell model. They are a continuous cell line that was isolated from rat leukemia
cells treated with β-chlorethylamine98. They are functionally homologous to human mast
cells97,98 and have the same core signaling machinery99,100. As a biosensor, RBL cells
have been used to test the environmental toxicity of various chemicals101. Substantial
research has been done with RBL cells to study IgE-FcεRI interactions and degranulation
signaling pathways102.
This study, as well as previous studies in the Gosse laboratory, makes use of
RBL-2H3 cells both because the line serves as good model for human mast cells and
because a large number of monoclonal RBL-2H3 cells can be produced by basic cell
culture technique. RBL-2H3 cells give a dose responsive curve after stimulation by DNPBSA antigen103, indicating that they are a good model for studying degranulation. A
similar response has also been reported in human basophils120.

1.7 Mast Cell Degranulation
As stated earlier, the primary function of mast cells in the immune system is to
release pro-inflammatory mediators through the process of degranulation (the release of
mediators from intracellular granules). Degranulation begins when allergen or antigen
10

bind to a sensitized mast cell104. Degranulation ends when the cells intracellular granules
have undergone exocytosis. Many of the key steps of degranulation, including ATP
priming steps, vesicles docking at release sites and fusing with the membrane, and the
release of the mediators, have been successfully imaged and analyzed using internal
reflection microscopy105.
In RBL-2H3 cells, degranulation can begin when either the receptor FcεRI is
activated by IgE bound to antigen, or when calcium is mobilized within the cell84. FcεRI
has both and α chain, a γ subunit, and a β chain, which spans the membrane four times106.
When IgE binds FcεRI, crosslinking occurs, spurring the phosphorylation of tyrosine
residues on the β and γ subunits by Lyn107. Syk then binds to the γ subunit of the receptor
and undergoes a conformational change. Syk then acts as a catalyst for a number of
phosphorylation reactions. This leads to the activation of the linker for T-cell activation
(LAT) and PI3K108. LAT recruits PLCγ1 to the membrane, where Syk phosphorylates it.
There, PLCγ1 serves as the catalyst for the hydrolysis of phosphatidylinositol 4,5bisphosphate (PIP2) to inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG)109.
DAG activates protein kinase C (PKC) while IP3 sets off an influx of intracellular
calcium by binding to the endoplasmic reticulum (ER). The ER then releases its store of
calcium. As the amount of calcium in the ER stores decreases, a conformational change
in STIM1 is spurred. STIM1 then interacts with calcium release activated calcium
(CRAC) channel/Orai1 in the plasma membrane, which allows for calcium to influx into
the cytoplasm110. With the use of Sarco/endoplasmic calcium ATPase (SERCA) pumps,
the ER stores of calcium are replenished, while the new higher level of intracellular
calcium is sustained. This is the key signal that leads to mast cell degranulation111.
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Mitochondria, which have a high calcium buffering capacity and specific tools for
calcium uptake and efflux, play a major role in the regulation of this signal112.
PKC phosphorylates the protein myosin, which stimulates the cytoskeleton
rearrangements in the cell that are needed for degranulation125. Intracellular calcium,
along with PKC, activates both isoforms of PLD121. PLD1 is involved in the movement
of granules within the cell, while PLD2 plays a role in the granule fusion to the cell
membrane126. All together, these many steps lead to mast cell degranulation.

1.8 Previous Research
Previous research done in the Gosse laboratory has shown that TCS disrupts
antigen and thapsigargin-stimulated degranulation in RBL-2H3 cells and calcium
ionophore-stimulated degranulation in human mast cells clone 1.2 (HMC-1.2), at noncytotoxic doses113,114. TCS was also found to disrupt antibody- and calcium ionophorestimulated degranulation in RBL-2H3 cells113. Based on its small molecular structure, its
hydrophobic properties, and its ionizable proton, it was theorized that TCS was a
mitochondrial uncoupler, and that a decrease in ATP production could be responsible for
the decreased degranulation response. Further research was done using a Toxglo assay
(Promega) to assess the ATP production of cells exposed to TCS. The research found
that, in glucose free, galactose-containing media, TCS significantly inhibited ATP
production in RBL-2H3 cells with an EC50 of 7.5 to 9.6 µM (95% confidence interval)114.
Similar studies done with HMC-1.2 cells found a similar effect with an EC50 of 4.2 to
13.7 µM (95% confidence interval)114. These effects were not observed in Toxglo assays
done in glucose media, where cultured cells can produce adequate energy from
glycolysis. ATP and degranulation response experiments were then done with triclosan12

methyl (mTCS), a derivative of TCS that have a methyl group in place of TCS’s
ionizable proton. mTCS, which again does not have an ionizable proton, was not found to
have any significant effect on either ATP production or degranulation114. In addition it
was found that TCS exposure led to an increase in oxygen consumption in RBL-2H3
cells114. All these pieces of evidence strongly suggested that TCS in a mitochondrial
uncoupler.
If TCS is a mitochondrial uncoupler, then it could pose a serious health risk to
those who come in contact with it. As mentioned earlier, the vast majority of U.S.
citizens are likely exposed to TCS. The purpose of my research was to investigate the
potential danger of TCS by comparing its mitochondrial uncoupling effect to that of the
known mitochondrial uncoupler DNP. This study focuses on characterizing DNP’s effect
on RBL-2H3 ATP production in the same conditions where TCS inhibited ATP
production. The Promega Toxglo assay, as well as several cytotoxicity assays, were
utilized. If TCS has a similar, or more potent, mitochondrial uncoupling effect in RBL2H3 cells, it could indicate that there is a serious health risk with using this antibacterial
product.

2. Materials and Methods
2.1 Cell Culture
RBL-2H3 cells (A gift from D. Holowka, Cornell University, Ithaca, NY, USA) were
cultured using the methods of Hutchinson et al127.
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2.2 Galactose Media Preparation
Glucose free, galactose containing media was used to plate cells 1-h before
exposure to DNP each day of an experiment. Galactose media contains 8.3 g l-1
Dulbeccos modified Eagle’s medium (DMEM; Sigma) without glucose, L-glutamine,
phenol red, sodium pyruvate or sodium bicarbonate. 10mM D-(+)-galactose (Sigma),
0.5842 g l-1 L-glutamine (Lonza, Alpharetta, GA, USA), and 3.7 g l-1 sodium bicarbonate
were added to this DMEM to complete the media. The media was then brought to a pH of
7.4 using a pH electrode and adding small amounts of sodium hydroxide and
hydrochloric acid. Bovine serum albumin (BSA; Calbiochem) was then added.

2.3 DNP Media Preparation
DNP was purchased from Sigma-Aldrich (St. Louis, MO, USA) (≥98%,
moistened with water 15%, CAS no. 51-28-5). A starting DNP stock was freshly
prepared each day of an experiment by dissolving DNP into cell culture, along with 3.7 g
l-1 sodium bicarbonate buffer (VWR), before bringing the pH of the solution to 7.4 using
a pH electrode and small amounts of sodium hydroxide and hydrochloric acid. This
dilution method avoids the use of organic solvents. After adjusting the pH, the DNP stock
was run through a 0.22µm filter to remove any particulate matter. The exact
concentration was then determined using ultraviolet-visible (UV-vis) spectrophotometry
and the Beer-Lambert equation. Absorbance was measured at 400 nm using a 1 cm path
length and an extinction coefficient of 12,100 M-1 Lcm-1 128,129. The components of
galactose media were then added in the same concentrations as in galactose media. BSA
was then added.
14

2.4 Adenosine Tri Phosphate Production Assay
ATP production was measured using a Promega (Madison, WI, USA) Toxglo kit,
following the methods described by Weatherly et al 114 with one exception. Based on the
suggestion of a Promega scientist that the cytotoxicity reagent was not necessary for ATP
measurement, the cytotoxicity reagent was not added. The cytotoxicity reagent from this
particular kit works by reacting with proteases released by lysed cells to produce a
fluorescence signal. Since DNP is a fluorescence quencher130, meaningful cytotoxicity
data could not be measured using this kit component.

2.5 Trypan Blue Cytotoxicity Assay with a 6-Well Plate
Cytotoxicity was measured using a trypan blue exclusion assay and a 6-well plate
(Grenier). This assay uses trypan blue dye (Lonza) which can penetrate an RBL cell’s
membrane. A healthy, living RBL cell will be able to pump the dye out, while an
unhealthy or dead cell will not. When examined under a microscope after trypan blue
exposure, healthy cells appear as distinct clear circles, while unhealthy cells appear as
dark indistinct blobs. With use of a hemocytometer and a microscope, it is thus possible
to assess the number of healthy cells in a sample that has been exposed to trypan blue
dye.
At the start of each experiment DNP media and galactose media were freshly
prepared as described earlier. A 6 mM stock of DNP media was then made using the
DNP and galactose media. From this stock, 3.5 mL dilutions were made of each
concentration of DNP that was to be tested.
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Cells were then harvested from a cell culture flask that had been prepared at least
two days prior to the experiment and plated on 6-well plates using galactose media. Cells
were plated at a density of 2 million to 3 million cells per well (depending on the number
of cells that were harvested from the flask), in 1 mL of sterile galactose media. Two wells
were plated for each concentration of DNP that was being tested. The cells were then put
in a 37°C, 5% CO2 incubator for 1-h in order to adhere to the plate.
After the hour, the plates were checked under the microscope in order to make
sure cells were alive and had adhered to the plate. Then 1 mL of each DNP dilution were
added to their designated well. The plates were then put back in the incubator for a 1-h
exposure period. After the exposure period, the DNP and media were removed from each
well. The wells were then washed with 1 mL of trypsin before another 1 mL of trypsin
was added to each well. The plate was then placed in the incubator for another 10
minutes in order to allow the trypsin to separate the cells from the plate. The cells were
then harvested, collected into samples, and quenched with galactose media. Next, 50 µL
of each sample was then added to 50 µL of trypan blue dye. From the resulting cell
solution, 50 µL was then taken and added to a hemocytometer. The number of living cells
was then counted by looking at the hemocytometer under the microscope. The total
number of living cells in a sample could then be calculated using the following equation.
Total number of cells = (dilution factor)(average number of living cells per
square millimeter)(10,000)( total volume of solution in mL)
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2.6 Trypan Blue Assay with a 96-well plate
Several attempts to measure cytotoxicity were done using a trypan blue exclusion
assay on a non-adherent, non-tissue culture treated, 96-well plate (Grenier, Falcon). This
assay uses the same principle as stated above.
At the start of each experiment DNP media and galactose media were freshly
prepared as described earlier. A 2 mM stock of DNP media was then made using the
DNP and galactose media. From this stock, 0.5 mL dilutions were made of each
concentration of DNP that was to be tested.
Cells were then harvested from a cell culture flask that had been prepared at least
two days prior to the experiment and plated on a 96-well plate using galactose media. A
concentration of 50,000 cells, in 50 µL of sterile galactose media, were then plated, in
random order, in each well. Three wells were plated for each concentration of DNP that
was being tested, as well as three wells for untreated control, and several mock wells. The
cells were then put in a 37°C, 5% CO2 incubator for 1-h.
After the hour, the plates were checked under the microscope in order to make
sure they were alive. Then 50 µL of each DNP dilution were added to their designated
well. The plates were then put back in the incubator for a 1-h exposure period. After the
exposure period, the DNP and media were removed from each well. After this hour the
plate was again looked at under the microscope to see if the cells were alive. Then 50 µL
of cells/media was removed from each well and added to 50 µL of trypan blue dye. 50 µL
was then taken from the resulting solution and then added to a hemocytometer. The
number of living cells was then counted by looking at the hemocytometer under the
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microscope. The total number of living cells in a sample could then be calculated using
the following equation.
Total number of cells = (dilution factor)(average number of living cells per
square millimeter)(10,000)( total volume of solution in mL)

2.7 Crystal Violet Assay
A crystal violet assay was done after a failed attempt to do a trypan blue assay
using a 96-well plate. The crystal violet assay is done using components of the FACE PI3
Kinase ELISA kit (Active Motif, Carlsbad, CA). This crystal violet component of this kit
is designed to bind and stain the nuclei of cells, producing an absorbance signal at 595
nm meters that is proportional to the total number of cells.
Cells were plated and exposed to DNP as described in that assay’s subsection.
Following the discovery that the RBL cells had adhered to the plate, the remaining media
and DNP in the plate was dumped. Each well was then washed twice with 200 µL of the
kit’s wash buffer and then another two times with 200 µL of 1X PBS buffer (Lonza). The
plate was then air dried for five minutes. After the five minutes 100 µL of crystal violet
dye was then added to each well and the plate was incubated for 30 minutes at room
temperature on a shaker. After the half hour, the crystal violet solution was dumped and
the each well was washed with 200 µL of 1X PBS buffer three times. During each of
these washes, the plate was placed on a plate shaker for five minutes. These washes are
designed to remove any crystal violet that is not bound to cells. After the third wash, 100
µL of 1% sodium dodecyl sulfate (SDS) solution was added to each well. In this assay
SDS solution is used to bring the cells with bound crystal violet dye into solution and
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then release the dye, providing an absorbance signal that can be read by the plate reader.
The plate was incubated on the plate shaker at room temperature for 1-h. After the hour,
the absorbance of each well at 595 nm was measured using the plate reader (BioTek).

2.8 Lactate Dehydrogenase Assay
A lactate dehydrogenase (LDH) assay was attempted in order to assess the
cytotoxicity of DNP. The assay was done using a kit from Roche Applied Science. This
assay works adding a dye solution and catalyst to RBL cells in a plate. The dye solution
reacts with LDH released by dead cells and produces an absorbance signal at 490 nm that
can be measured using a plate reader. The more dead cells there are, the higher the
absorbance will be. In addition to cells being exposed to varying concentrations of DNP,
there are also low control cells (unexposed to any toxicant) and high control cells (cells
exposed to a lysis solution).
At the start of each experiment DNP media and galactose media were freshly
prepared as described earlier. A 2 mM stock of DNP media was then made using the
DNP and galactose media. From this stock, 0.5 mL dilutions were made of each
concentration of DNP that was to be tested. Aliquots of kit components were thawed on
the day of each experiment.
Cells were then harvested from a cell culture flask that had been prepared at least
two days prior to the experiment and plated on a 96-well plate using galactose media. A
concentration of 50,000 cells, in 50 µL of sterile galactose media, were then plated, in
random order, in each well. Three wells were plated for each concentration of DNP that
was being tested, as well as three wells for low control and three wells for high control.
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The cells were then put in a 37°C, 5% CO2 incubator for 1-h in order to adhere to the
plate.
After the 1-h, 50 µL of the varying DNP dilutions were added to the
corresponding wells on the plate. Plain galactose media was added to the control wells.
The plate was then placed back in the incubator for 45 minutes. After the 45 minutes the
plate was removed from the incubator and 5 µL of lysis solution was quickly added to
three high control wells. The plate was then placed back in the incubator for another 15
minutes. During that time the dye solution and catalyst were brought into solution with
each other to make a reaction mixture. After the 15 minutes, the plate was removed from
the incubator and 100 µL of reaction mixture was added to each well. The plate was then
incubated for 30 minutes at room temperature. Following the 30 minutes, 50 µL of stop
solution was added to each well. The absorbance at 490 nm was then measured for each
well using the plate reader.

2.9 Data Analysis
Data from the ATP production assay were analyzed by first averaging the
luminescence value of the three replicates of each sample from one experiment. Those
averages were then compared to the average of the untreated control replicates. This
comparison was expressed as a percentage of the untreated control. Those data were then
entered into GraphPad Prism software to produce a figure. The data were analyzed using
a one-way ANOVA followed by Tukey’s post-hoc test to determine statistical
significance.
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Data from the trypan blue assay were analyzed first by calculating the total
number of cells from each sample. The total number of living cells from each DNP
replicate was then averaged together. That number was then compared to the average of 0
mM DNP (serving as the low control) and that comparison was the expressed as a
percentage. Those data were then entered into GraphPad Prism software to produce a
figure. The data were analyzed using a one-way ANOVA followed by Tukey’s post-hoc
test to determine statistical significance.
Data from the crystal violet assay were analyzed by averaging the absorbance at
595 nm each of the replicates for each sample. These averages, along with the averages
for the control, were then entered into GraphPad Prism software to produce a figure.
Data from the LDH assay were analyzed first by averaging the absorbance at 490
nm from each of the replicates for each sample, as well as the high and low controls.
Those averages were then compared to the average of the untreated control replicates.
This comparison was expressed as a percentage of the untreated control. Those data were
then entered into GraphPad Prism software to produce a figure. Additionally, to assess
whether an assay’s results were valid, the average of the high control was divided by the
average of the low control. If this ratio was at least 20, then the results were considered
valid131.
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3. Results
3.1 Determining the Most Effective Technique for Dissolving
DNP
In order to perform any experiments with DNP, it is necessary to get DNP into a
uniform solution. Literature suggested that DNP was soluble in water at concentrations
up to 15-30 mM132,133. Initially DNP was brought into solution simply by weighing out a
0.037 g of DNP, adding it to 20 mL of cell culture water (Lonza), and then vortexing and
inverting the solution. The resulting solution should be 8.5 mM DNP (DNP supplied by
Sigma is 15% wetted with water). The exact concentration was determined using UV-Vis
spectrophotometry and an extinction coefficient (12,100 M-1Lcm-1) from Peralta et al129.
However, this initial technique only resulted in solutions that were around 4 mM. A more
effective way of dissolving DNP was needed.
In order to determine a more effective way, four dissolving techniques were
tested: changing the pH to 7.4 (physiological pH), sonicating for 90 minutes, stirring for
90 minutes at room temperature, and stirring for 90 minutes at 50°C. An approximately
8.5 mM DNP solution was prepared as described earlier before each method was tested.
Exact concentration was determined before and after each technique was used. Changing
the pH of DNP in solution by itself did not work because DNP has a low pKa of 3.9134.
Sonicating for 90 minutes resulted in a solution that was 4.73 mM, stirring the solution at
room temperature for 90 minutes resulted in a 3.69 mM solution, and stirring the solution
at 50°C resulted in a 3.90 mM solution. These results indicate that none of these
techniques were particularly effective.

22

It was then decided to try adjusting the pH of DNP in the presence of a buffer.
Sodium bicarbonate buffer was chosen since it was the same buffer used in the galactose
media that was prepared for Toxglo assays, and because it has a pKa of 6.4, which is
much closer to the target pH of 7.4. Using UV-Vis spectrophotometry it was determined
that sodium bicarbonate did not produce absorbance in the same range as DNP, so it
would not interfere with determining the concentration of DNP. To test this technique, an
8.5 mM solution of DNP was again prepared as described earlier, but this time in the
presence of 44 mM sodium bicarbonate. The pH was measured using a pH electrode
meter, and the pH was adjusted adding small amounts of sodium hydroxide and
hydrochloric acid with a Pasteur pipette. The resulting solution was 5.78 mM. This result,
compared with the previous results, indicated that this method of dissolving DNP was by
far the most effective, and was the dissolving technique that was used for all the
following experiments.

3.2 DNP Effect on Cellular ATP production
ATP production was measured in RBL-2H3 mast cells (RBLs) using the
techniques mentioned in Materials and Methods. Combined data from at least four
different experiments for each concentration indicate that DNP inhibits ATP production
in RBL cells significantly, with an EC50 between 389 µM and 677 µM (median 533 µM)
as seen in Figure 1. Cytotoxicity experiments (see below) indicate that the concentrations
of DNP used are non-cytotoxic, indicating that the decrease in ATP is due to
mitochondrial uncoupling and not cell death. Previous research done under the same
conditions from Weatherly, et al114 indicate that TCS inhibits ATP production with an

23

EC50 of 8.6 µM. Together, these results show that TCS decreases ATP production in RBL
cells at concentrations that are 62 times lower than DNP’s EC50 for ATP production.
These data suggest that TCS is a much more potent mitochondrial uncoupler of mast cells
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Figure 1. ATP production in RBL cells exposed to increasing concentrations of DNP. ATP production
was measured in RBL cells after exposure in galactose media for one hour. Percent of untreated control
for ATP production is determined by dividing the luminescence value of the sample by the average of
the untreated control. The values presented are the means ±SEM of at least four different experiments;
each with three replicates. Statistically significant results, as compared to untreated control, are indicated
by **P<0.01, and ***P<0.001 as determined by one way ANOVA followed by Turkey’s post-hoc test.
RBL, rat basophilic leukemia (mast cell), DNP, 2,4-Dinitrophenol.
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No-cell control experiments done to test whether DNP disrupts background
luminescence levels in the ToxgloTM assay indicate no significant effect of DNP on these
values (Figure 2A). Control experiments done to test whether DNP interferes with the
ATP reagent also indicated no disruptive effect of DNP (Figure 3A). These data indicate
that the decrease in luminescent signal in Toxglo experiments is due to decreased ATP
production and not signal interference.
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Figure 2. Controls to examine whether DNP disrupts background luminescence levels (A) and/or
background fluorescence (B) in the ToxgloTM assay. All steps were from the Toxglo assay described by
Weatherly, et al. were followed, with the lone modification being that no cells were plated. (A) Raw
luminescence values, following treatment with ± 1mM DNP. The values are low, due to the lack of
cells, and thus, lack of ATP production. DNP does not change these values. (B) Raw fluorescence
values from the control experiment, ± 1mM of DNP. These values are moderate, likely due to
background cleavage of the cytotoxicity substrate, even in the absence of cells. These data show that
DNP dampens fluorescence at the wavelength used for the assay, meaning that use of this particular
assay to assess the cytotoxicity of DNP is not viable. The values presented are means ± SEM of three
independent experiments, each with three replicates. Statistically significant results, as compared to 0
mM DNP, represented by *P<0.05, are determined by one-way ANOVA followed by Tukey’s post-hoc
test. DNP, 2,4-Dinitrophenol.
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Figure 3. Controls to determine whether DNP interferes with either the ATP reagent (A) cytotoxicity
reagent (B). (A) For the ATP reagent controls, the ToxgloTM procedure described by Weatherly, et al.
was followed with the following changes: Cells were incubated for 1-h with plain media, not
containing DNP. After discarding the media, ATP reagent, which lyses the cells, was added, followed
immediately by the varying DNP concentrations. This was done to test whether DNP affects the ATP
luminescence reaction without affecting cellular ATP production. Results indicate that DNP does not
significantly affect this reaction. (B) For the substrate-protease control, the steps described by
Weatherly, et al. were followed with two exceptions. The first being that black, clear bottom plates
(Grenier) were used, and the second being that digitonin, which lyses cells, was added to all wells
before DNP exposure. Fluorescence was then measured to determine whether DNP interfered with the
substrate protease reaction. Results show that DNP does not significantly alter this reaction, in contrast
to the no cell control experiments (Figure 2). Values presented are means ±SEM of three independent
experiments, each with three replicates. No significance, as compared to untreated control, was
determined by one-way ANOVA, followed by Tukey’s post-hoc test. DNP, 2,4-Dinitrophenol.
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3.3 DNP Interference with Cytotoxicity Measurement
In order to determine the potency of DNP as a mitochondrial uncoupler, it is
necessary to be able to assess its cytotoxicity, in order to determine if any decrease in
ATP production is due to inhibition of oxidative phosphorylation, or cell death. Initially,
cytotoxicity was assessed using a proprietary cytotoxicity reagent provided within the
Toxglo assay kit (Promega). This reagent reacts with a protease released only by lysed
(dead) cells135. This reaction produces a fluorescent signal135. Initial experiments yielded
cytotoxicity data like those seen in Figure 4. Note that the cytotoxicity shows a linear
regression as the concentration of DNP increases. This would indicate that the
cytotoxicity of DNP actually decreases at higher DNP concentrations. These results were
surprising, given that DNP is a known dangerous compound.
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Figure 4. Cytotoxicity of RBL cells exposed to increasing concentrations of
DNP in galactose media, measured by the ToxgloTM assay. Percent of untreated
control for cytotoxicity is determined by dividing the fluorescence value of the
sample by the average of the untreated control. The values presented are means
±SEM of three replicates from one experiment. Statistically significant results, as
compared to untreated control, are indicated by ***P<0.001, as determined by
one way ANOVA followed by Turkey’s post-hoc test. RBL, rat basophilic
leukemia, DNP, 2,4-Dinitrophenol.

Control experiments were done to determine whether DNP interferes with the
cytotoxicity reagent-protease reaction. Control experiments done in the presence of cells
indicated no significant interference (Figure 3B). However, no-cell control experiments
indicated significant interference at the high concentrations of DNP utilized (Figure 2B).
Further investigation of DNP in the literature led to the published fact that DNP is a
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fluorescence quencher130. This revelation, coupled with the data from initial and control
experiments, indicated that a new way of determining DNP cytotoxicity was needed.

3.4 Determining the Cytotoxicity of DNP
A trypan blue exclusion assay using a 96-well plate was initially used to
determine cytotoxicity. RBL cells were plated on a clear, 96-well, non-adherent, nontissue culture treated plate and exposed to varying concentrations of DNP as described in
Materials and Methods. However, when samples were collected from the plate and
counted after the DNP exposure period, there were almost no cells. This was true of not
only the samples from wells exposed to DNP, but also of the control wells that were not
exposed to any toxicant. The plate was then observed under a microscope, and a fairly
confluent lawn of cells was observed in all the wells that had had cells plated in them.
While looking at them under the microscope, the cells remained stagnant even when the
plate was shaken. These same observations were noted in two separate experiments.
These observations indicated that, in spite of the plate being designed to prevent cell
adherence, the RBL cells had adhered to the plate.
After the second failed trypan blue assay, a crystal violet assay was done using
the adhered cells from the second trypan blue experiment using the techniques described
in Material and Methods. Data from the crystal violet assay indicate that there is no
significant change in DNP cytotoxicity at concentrations of up to 100 µM (Figure 5).
This experiment included three replicates for each concentration of DNP assessed. These
results were promising, but not definitive. The trypan blue assay was not working, so
another assay was attempted.
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Figure 5. Cytotoxicity of 1-h DNP exposure assessed by absorbance at 595nm after
staining with crystal violet dye. After plating cells on a clear, non-adherent plate and
a 1-h exposure to DNP, an attempt was made to count living cells, collected in
samples from the plate, using trypan blue staining. However, before counting was
done, it was determined that the RBL cells had adhered to the non-adherent plate,
preventing samples from being collected from the plate. The adhered cells were then
stained using crystal violet dye, and cytotoxicity was assessed as described in
Materials and Methods. No significant changes in cytotoxicity were observed among
the concentrations of DNP used. Values presented are the means of three replicates
from the plate. DNP, 2,4-Dinitrophenol.

A lactate dehydrogenase (LDH) assay was used next performed as described in
Materials and Methods. The data from three independent LDH assays (Figure 6), each
with three replicates, show a decrease in cytotoxicity for every concentration tested, as
well as a couple of very large decreases at higher concentrations. As with the cytotoxicity
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measured using the Toxglo reagent, these results did not seem to make sense. The
validity of the results was then tested by measuring the ratio of absorbance from the high
control (fully lysed cells) and low control (untreated cells) samples. A valid test would
have an absorbance ratio of at least 20. The three experiments that I ran had ratios that
ranged from 1.5 to 2.5. A graduate student (Lisa Weatherly) then performed the same
experiment under the same conditions and got similarly confusing results (not shown).
Combined, these results indicated that the assay was not working properly and, yet again,
another way of measuring cytotoxicity was needed.
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Figure 6. Cytotoxicity of 1-h exposure to DNP measured using Cytotoxicity Detection Kit (LDH)
from Roche. Values Presented are means ±SEM of three different experiments. Based on three
very low ratios of high control (fully lysed cells) to low control (untreated cells), it was
determined that all three tests were invalid. The low ratio was most likely due to DNP interfering
with the absorbance signal that this assay depends on to measure cell lysis. DNP, 2,4Dinitrophenol, LDH, Lactate dehydrogenase.
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The next method used was another trypan blue assay, but this time using tissue
culture-treated 6-well plates (which have much larger well areas than do 96-well plates).
This assay was performed as described in Materials and Methods. Initial results (not
shown) were only slightly better than the original trypan blue assays, however the cell
harvesting technique was gradually improved upon by experience and a workable version
of the assay was developed. Data from five viable tests show no significant change in
RBL cytotoxicity at DNP concentrations up to 3mM (which was the absolute highest
concentration used in the DNP Toxglo experiments). These data indicate that the
concentrations used in the Toxglo assay were, in fact, non-cytotoxic. Combined with the
Toxglo ATP data, these data indicate that the DNP’s inhibition of ATP production was
likely due to DNP’s mitochondrial uncoupling effect.
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Figure 7. Cytotoxicity of 1-h exposure to DNP in galactose media measured using a
trypan-blue exclusion cytotoxicity assay. Percent of cells alive is determined by
dividing the number of remaining living cells in a sample by the average number of
living cells in an untreated control (0 mM DNP). Values expressed are means ±SEM
of 5 independent experiments, each with two replicates per treatment. Statistically
significant results (or lack thereof) were determined by one way ANOVA followed by
Tukey’s post-hoc test. DNP, 2,4-Dintrophenol.

4. Discussion
Weatherly et al. found that the ubiquitous antimicrobial agent triclosan inhibits
ATP production, in a variety of cell types, including in RBL-2H3 mast cells, at noncytotoxic levels114. This finding was part of a larger study which showed that TCS is a
proton ionophore mitochondrial uncoupler. In the current study, we have determined the
concentrations at which 2,4-dinitrophenol, a canonical mitochondrial uncoupler, inhibits
ATP production in RBL cells (Figure 1), in order to allow comparison of the EC50 values
of TCS and DNP in the RBL cell line. In order to assess if a chemical is a mitochondrial
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uncoupler, it is necessary to confirm that the decline in ATP production is not due to cell
death. If a decline in ATP production corresponds with an increase in cytotoxicity, then
the decline is likely due simply to the toxicant’s killing the cells.
In this study, a variety of methods were employed in order to assess the
cytotoxicity of DNP on RBL-2H3 cells. Initial experiments done with the fluorescencebased cytotoxicity reagent component from the Toxglo kit yielded data which showed a
decline in cytotoxicity due to increasing DNP doses (Figure 4). These data were
confusing, and it was later discovered via literature searches that DNP is a fluorescence
quencher130, explaining the decline in fluorescent signal with higher concentrations of
DNP (Figure 2B). An LDH assay was also unsuccessful in assessing cytotoxicity due to
DNP interference with that kit’s reagent (Figure 6). Ultimately a refined trypan-blue
exclusion assay generated data that indicated that DNP does not cause cell death, even at
concentrations up to 3 mM (Figure 7). These data can be reasonably assumed to be
accurate based on both the quantified data of 5 different experiments, none of which
indicate an increase in RBL cytotoxicity due to DNP exposure, along with the qualitative
observation that there was no visible change in the number of cells exposed to each
concentration of DNP. If DNP is not cytotoxic at concentrations ranging from 500 µM to
3 mM, then it is reasonable to assume that the lower concentrations of DNP used to
assess ATP production are also not cytotoxic, and that the observed decline in ATP
production is very likely due to mitochondrial uncoupling. Since the decline in ATP
production, caused via DNP exposure, appears to be due to mitochondrial uncoupling, it
can be used as a meaningful comparison to data generated from previous experiments
done under the same conditions with TCS.
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Mitochondrial uncouplers disrupt ATP production via oxidative phosphorylation
by separating the energy produced by the electron transport chain (stored in the proton
gradient across the inner mitochondrial membrane) from ATP synthesis77. The
mitochondrial Toxglo assay (Promega) effectively measures ATP production using a
luminescent signal, and is one way of assessing whether a test compound is a
mitochondrial uncoupler (when data is paired with corresponding cytotoxicity data)77.
Previous studies done by the Gosse laboratory have shown that TCS decreases ATP
production in a variety of cell lines, including RBL-2H3, in glucose-free, galactosecontaining media114. In RBL-2H3 cells, the EC50 of TCS’s ATP production is 7.5 to 9.6
µM. This result, along with data showing that TCS increases oxygen consumption in
RBL cells114 and decreases mitochondrial membrane potential (Lisa Weatherly, personal
communication), provide strong evidence that TCS is a mitochondrial uncoupler. In this
study, we show that DNP significantly decreases ATP production in RBL-2H3 cells, as
would be expected for a mitochondrial uncoupler, but only at much higher EC50 than that
of TCS. The EC50 for DNP’s inhibition of ATP production in RBL cells is 389 µM to 677
µM (Figure 1). A comparison of the median EC50 values shows that, in RBL mast cells,
62-fold less TCS than DNP is required to inhibit ATP production. These results indicate
that TCS could be a much more potent mitochondrial uncoupler than DNP, but more
research is needed before anything definitive can be stated. Future studies might
investigate how DNP affects the oxygen consumption rate of RBL-2H3 cells under
similar conditions and if the same extent of differential TCS vs. DNP EC50 values are
seen in additional cell types, including primary human cells. Experiments could also be
done to see if DNP exposure inhibits RBL cell degranulation at doses similar to TCS.
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One thing to note is the fact that DNP is notoriously toxic chemical, yet was
found to be both a less potent mitochondrial uncoupler than TCS and non-cytotoxic to
RBL-2H3 cells at concentrations up to 3 mM. In a similar experiment utilizing a trypan
blue assay, TCS was found to cause significant cytotoxicity at 150 µM113. One possible
explanation for the seemingly dampened effects of DNP is its low pKa of 3.9134. The
experiments in this study were done at a pH of 7.4. It is possible that under these
conditions, the DNP was highly deprotonated, according to the Henderson-Hasselbalch
equation. When deprotonated, proton ionophore mitochondrial uncouplers take on a
negative charge and cease to be lipophilic, losing their ability to diffuse across the inner
mitochondrial membrane, and thus their ability to disrupt the proton gradient. DNP is
actually capable to delocalizing its negative charge across its entire structure when
deprotonated, thus maintaining its lipophilic properties and its ability to diffuse across the
inner membrane of the mitochondria77. However, when it is deprotonated, it no longer
can carry a proton, and thus it cannot disrupt the proton gradient. TCS has a pKa of 7.9
and thus would not be nearly as deprotonated under these conditions, and would maintain
its mitochondrial uncoupling ability. This theory might explain the results of this
experiment, but it fails to account for the fact that ingestion of DNP can cause enough
mitochondrial uncoupling to induce hyperthermia in humans, whose natural internal pH
is approximately 7.4.
Previous research has been done by Lisa Weatherly with the other canonical
mitochondrial uncoupler carbonyl cyanide 3-chlorophenylhydrazone (CCCP) under the
same or similar experimental conditions114. Her data show that, like TCS, CCCP inhibits
RBL degranulation. Her data also show that CCCP inhibits ATP production in RBL cells
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with an EC50 of 0.8 µM to 1.6 µM, much lower than the comparable TCS EC50114. 1 µM
of CCCP was also shown to increase oxygen consumption in RBL cells at a similar rate
to 10 µM TCS114. It is interesting to note that, unlike DNP, the known mitochondrial
uncoupler CCCP inhibits ATP production at much lower concentrations than TCS and
suggests that mitochondrial uncoupling effect of DNP may be decreased in these
particular experimental conditions.
Currently there have been some, though not a large body of research into the
possible adverse effects of prolonged TCS exposure. Studies have found links between
TCS exposure and increased incidence of allergy and asthma62-64, decreased fertility65,
and developmental issues67. Other studies have found no connection between use of TCScontaining products and hormone-related health problems69-71. More research is needed to
be done to determine whether the use of TCS in personal care products is dangerous, but
the findings of this study, along with those from previous studies, indicate that there is a
strong possibility that TCS use poses a significant threat to human health.
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